Bloomberg Law
Pharmaceutical & Life Sciences News

Latest Stories

Bayer-Backed Drug Maker Boundless Bio Raises $100 Million in IPO

<-rte-company state="{"_id":"0000018e-8237-dd73-a18e-c7379ceb0000","_type":"00000160-4b23-d8bd-adfd-4b3348fd0000"}">Boundless Bio Inc., a cancer therapeutics maker that counts <-rte-company state="{"_id":"0000018e-8237-dd73-a18e-c7379ceb0001","_type":"00000160-4b23-d8bd-adfd-4b3348fd0000"}">Bayer AG among its largest investors, raised $100 million in a US initial public offering after pricing shares at the midpoint of a marketed range.

Valsartan Adulteration Lawsuit Sees Most Claims Head to Trial

Labels identifying drugs as valsartan constituted express warranties about the medications’ safety, but whether manufacturers breached the warranty depends on disputed facts, a federal judge said ahead of a bellwether trial in litigation alleging generic blood pressure medications were contaminated by a carcinogenic substance.

PRACTITIONER INSIGHTS

View More Insights